Positron (OTCMKTS:POSC) Trading Down 4.7% - Should You Sell?

Key Points

• Stock down 4.7% — Positron fell to $1.81 on Thursday with 37,479 shares traded (slightly below average), and its 50‑day/200‑day moving averages are $2.03 and $1.72 respectively.
• Weak quarterly results and valuation — The company reported a ($0.22) EPS loss and just $0.11 million in revenue for the quarter, resulting in a negative P/E (−22.63) and a market cap of about $59.5 million.
• Business focus — Positron is a nuclear medicine firm specializing in cardiac PET imaging and the Attrius PET scanner, offering clinical, technical and financing services to healthcare providers.

Positron Corp. (OTCMKTS:POSC - Get Free Report)'s stock price fell 4.7% on Thursday . The stock traded as low as $1.80 and last traded at $1.81. 37,479 shares were traded during mid-day trading, a decline of 6% from the average session volume of 39,936 shares. The stock had previously closed at $1.8986.

Positron Trading Down 4.7%

The firm has a fifty day simple moving average of $2.03 and a two-hundred day simple moving average of $1.72. The stock has a market cap of $59.46 million, a PE ratio of -22.63 and a beta of 0.11.

Positron (OTCMKTS:POSC - Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($0.22) earnings per share for the quarter. The company had revenue of $0.11 million during the quarter.

About Positron

Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.